Growth Control and Anti-Cancer Mechanisms
Growth Control and Anti-Cancer Mechanisms
批准号:
7760644
负责人:
STEVEN ZHENG
金额:
$29.55万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-04-01 至 2012-01-31
关键词:
AccountingAntineoplastic AgentsAreaBiogenesisCell CountCell NucleolusCell ProliferationCellsCellular StructuresClinical TrialsConsumptionCytoplasmDNA-Directed RNA PolymeraseDataDrug Delivery SystemsEmployee StrikesGenesGenetic TranscriptionGoalsGrowthGrowth FactorHumanLeadMalignant NeoplasmsMossesNuclearNutrientOncogene ProteinsPTEN geneProcessProtein BiosynthesisProtein p53ProteinsProto-OncogenesRNARapamycin-Binding ProteinsRecombinant DNAResistanceRetinoblastomaRetinoblastoma ProteinRibosomal RNARibosomesSirolimusSiteStructureTherapeuticTumor Suppressor Proteinsanti-cancer therapeuticcancer cellcell growthcondensinneoplastic cellpreventpromotertumorigenesis
中文摘要
生长是通过积累新合成的蛋白质来增加细胞质量和大小的过程。是
越来越多地被认为是肿瘤发生中的一个重要过程,这是支持肿瘤快速生长所必需的。
癌细胞增殖(细胞数量增加)。蛋白质合成速率由两者决定
翻译起始和核糖体的丰度。产生核糖体或核糖体生物发生
涉及数百个基因和所有三种RNA聚合酶,占核转录的90%。
核糖体生物合成是高度耗能的,并且受到生长因子和营养物质的严格控制。它
早已知道,在癌细胞中,翻译机制的组分被去调节,
表达错误几种肿瘤抑制因子和原癌基因,如视网膜母细胞瘤(Rb)蛋白,
p53、PTEN和Myc已显示靶向核糖体生物发生。雷帕霉素是一种很有前途的新的
目前正在进行大规模临床试验的抗癌药物。它具有良好的耐受性,并显示出极好的疗效,
许多人类癌症。我们最近获得的证据表明,抑制核糖体的生物合成是至关重要的
雷帕霉素抑制细胞生长,并发现了几个新的机制,雷帕霉素抑制细胞生长,
核糖体生物发生在本研究中,我们将探讨核糖体的调控机制
生物发生、核仁大小控制和雷帕霉素抑制。这些目标的实现应
对生长控制、肿瘤发生和雷帕霉素作用机制的理解。此外,本发明还
这些研究可能会导致更有效抗癌治疗策略,并有助于确定新的癌症药物
这是癌症治疗中重要但研究较少的领域。
英文摘要
Growth is the process to increase cell mass and size by accumulation of newly synthesized proteins. It is
increasingly appreciated as an important process in tumorigenesis, which is required to support the rapid
cancer cell proliferation (an increase in cell number). The rate of protein synthesis is determined by both
translational initiation and the abundance of ribosomes. Producing ribosomes or ribosome biogenesis
involves several hundred genes and all three RNA polyrinerasesand accounts for 90% nuclear transcription.
Ribosome biogenesis is highly energy-consuming and is tightly controlled by growth factors and nutrients. It
has been long known that, in cancer cells, components of the translational machinery are deregulated or
misexpressed. Several tumor suppressors and proto-oncogenes, such as the retinoblastoma (Rb) protein,
p53, PTEN and Myc, have been shown to target ribosome biogenesis. Rapamycin is a promising new
anticancer drug currently under large clinical trials. It is well tolerated and has shown excellent efficacy for
many human cancers. We have recently obtained evidence that inhibition of ribosome biogenesis is crucial
for rapamycin to inhibit cell growth, and discovered several new mechanisms for rapamycin to inhibit
ribosome biogenesis. In this proposal, we will investigate the regulatory mechanisms of ribosome
biogenesis, nucleolar size control and rapamycin inhibition. Accomplishment of these goals should advance
the understanding of growth control, tumorigenesis and the mechanism of action by rapamycin. Additionally,
such studies may lead to more effective anticancer therapeutic strategies and help identify new cancer drug
targets in this important yet poorly studied area in cancer therapeutics.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Oncogenic Chromatin Remodeling and Anticancer Mechanisms
-
批准号:10646923
-
项目类别:
-
资助金额:$45.31万
-
财政年份:2023
-
负责人:STEVEN ZHENG
-
依托单位:
Metabolic Control and Anticancer Mechanism
-
批准号:10198112
-
项目类别:
-
资助金额:$34.12万
-
财政年份:2021
-
负责人:STEVEN ZHENG
-
依托单位:
Metabolic Control and Anticancer Mechanism
-
批准号:10373070
-
项目类别:
-
资助金额:$33.43万
-
财政年份:2021
-
负责人:STEVEN ZHENG
-
依托单位:
Metabolic Control and Anticancer Mechanism
-
批准号:10661493
-
项目类别:
-
资助金额:$33.43万
-
财政年份:2021
-
负责人:STEVEN ZHENG
-
依托单位:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
-
批准号:10461838
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2020
-
负责人:STEVEN ZHENG
-
依托单位:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
-
批准号:10266843
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2020
-
负责人:STEVEN ZHENG
-
依托单位:
Amino Acids-Rab1A Nutrient Signaling in the Regulation of Glucose Homeostasis
-
批准号:10684889
-
项目类别:
-
资助金额:$38.27万
-
财政年份:2020
-
负责人:STEVEN ZHENG
-
依托单位:
Role of Rab1 in Cell Growth and Cancer
-
批准号:8583926
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2013
-
负责人:STEVEN ZHENG
-
依托单位:
Role of Rab1 in Cell Growth and Cancer
-
批准号:8721369
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2013
-
负责人:STEVEN ZHENG
-
依托单位:
Role of Rab1 in Cell Growth and Cancer
-
批准号:8842946
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2013
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:8761387
-
项目类别:
-
资助金额:$2.43万
-
财政年份:2013
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:8387927
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:9052739
-
项目类别:
-
资助金额:$32.99万
-
财政年份:2012
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:8700914
-
项目类别:
-
资助金额:$25.99万
-
财政年份:2012
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:8508219
-
项目类别:
-
资助金额:$4.99万
-
财政年份:2012
-
负责人:STEVEN ZHENG
-
依托单位:
Mechanism of Action by mTOR Kinase Inhibitors in Colorectal Cancer
-
批准号:8657934
-
项目类别:
-
资助金额:$32.0万
-
财政年份:2012
-
负责人:STEVEN ZHENG
-
依托单位:
Growth Control and Anti-Cancer Mechanisms
-
批准号:8018674
-
项目类别:
-
资助金额:$28.66万
-
财政年份:2007
-
负责人:STEVEN ZHENG
-
依托单位:
Growth Control and Anti-Cancer Mechanisms
-
批准号:7263307
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2007
-
负责人:STEVEN ZHENG
-
依托单位:
Growth Control and Anti-Cancer Mechanisms
-
批准号:7554656
-
项目类别:
-
资助金额:$29.55万
-
财政年份:2007
-
负责人:STEVEN ZHENG
-
依托单位:
Growth Control and Anti-Cancer Drug Mechanisms
-
批准号:8700894
-
项目类别:
-
资助金额:$23.94万
-
财政年份:2007
-
负责人:STEVEN ZHENG
-
依托单位:
海外基金